VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is scheduled to review the Company's New Drug Application for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on October 17, 2011 seeking approval to market Qnexa in the United States.
The FDA accepted the NDA for review on November 3, 2011. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.